Caris Life Sciences (CAI) vs Veracyte (VCYT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Veracyte (VCYT) has outperformed Caris Life Sciences (CAI) over the past year, gaining 24.2% versus a loss of 16.5%. Caris Life Sciences is the larger company by market cap ($8.40 billion vs $3.64 billion), about 2.3 times the size. On valuation, Veracyte trades at a lower forward P/E (23.2x vs 80.5x for Caris Life Sciences).
Veracyte converts more of its revenue into profit, with a net margin of 12.8% versus -8.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CAI | VCYT |
|---|---|---|
| Share price | $29.70 | $45.23 |
| Market cap | $8.40B | $3.64B |
| 1-day change | +8.00% | +3.74% |
| YTD return | +1.93% | +3.56% |
| 1-year return | -16.54% | +24.22% |
| 5-year return | — | -3.45% |
| P/E ratio (TTM) | 17.57 | 32.31 |
| Forward P/E | 80.46 | 23.25 |
| EPS (TTM) | $1.69 | $1.40 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $812.03M | $517.14M |
| Revenue growth (YoY) | +96.97% | +16.01% |
| Net income (latest FY) | $-68.09M | $66.35M |
| Gross margin | — | 70.10% |
| Operating margin | 5.56% | 11.17% |
| Net margin | -8.38% | 12.83% |
| 52-week high | $33.65 | $60.91 |
| 52-week low | $14.19 | $29.46 |
| Distance from 52-week high | -11.74% | -25.74% |
| Analyst consensus | buy | buy |
| Avg. price target upside | -2.09% | +29.16% |
| Average volume | 4.94M | 1.36M |
| Shares outstanding | 282.68M | 80.39M |
| Employees | 1,846 | 755 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Caris Life Sciences is about 2.3 times larger than Veracyte by market value ($8.40B vs $3.64B).
- VCYT has outperformed CAI by 40.8 percentage points over the past year.
- Veracyte trades at a higher earnings multiple (32.3x vs 17.6x trailing P/E).
- Veracyte is more profitable, keeping 12.8 cents of every revenue dollar as net income versus -8.4 cents for Caris Life Sciences.
- Caris Life Sciences grew revenue faster in its latest fiscal year (+96.97% vs +16.01%).
About Caris Life Sciences
CAI stock →Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms.
Health Care · Medical Specialities · 1,846 employees
About Veracyte
VCYT stock →Veracyte, Inc. operates as a diagnostics company in the United States and internationally.
Health Care · Medical Specialities · 755 employees
CAI vs VCYT FAQ
Which is bigger, Caris Life Sciences or Veracyte?
Caris Life Sciences (CAI) is larger, with a market capitalization of $8.40B compared with $3.64B for Veracyte (VCYT).
Which stock has performed better over the past year, CAI or VCYT?
VCYT returned +24.22% over the past 12 months, compared with -16.54% for CAI (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, CAI or VCYT?
CAI has the lower trailing P/E at 17.6, versus 32.3 for VCYT. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Caris Life Sciences and Veracyte in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.